Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) more frequently
affect elderly patients with a median age of 70 years and usually have a grim prognosis [1 …

Hematopoietic stem cell transplantation (HCT) is indicated for patients with higher-risk (HR)
myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Age, performance …

The outcome of persons> 65 years with acute myeloid leukemia (AML) is poor. A transplant
from an HLA-identical sibling or an HLA-matched unrelated donor can cure some of these …

Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often
undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for …

Acute Myeloid Leukemia (AML) is a disorder affecting primarily elderly individuals and
poses significant treatment challenges. Much has been learned about the underlying …

Older patients are generally, and arbitrarily, defined as those aged 60 and above. It is
important to recognise that the effect of age is modulated by numerous other prognostic …

In this retrospective study, 63 patients> 60 years with hematological malignancies and
treated with allo-SCT and with reduced-intensity conditioning (RIC) were reviewed. A total of …

Due to perceived intolerance, many elderly AML patients do not receive therapy, and few
are considered for hematopoietic cell transplantation (HCT). To better understand “real …

With a median age at diagnosis of approximately 65–70 years, acute myeloid leukemia
(AML) represents a major therapeutic challenge in the elderly. Only 30–35% of elderly …

Acute myeloid leukemia (AML) most commonly affects patients older than 60 years.
Outcomes of treatment of older AML patients have been poor. The advent of reduced …